Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Bao Pharma Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Bao Pharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
9 min read
Arrotex Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Arrotex Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
EGIS Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of EGIS Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
Amoytop Biotech Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Amoytop Biotech, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
EA Pharma Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of EA Pharma Co., Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
Abogen Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Abogen Biosciences, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
Fuji Pharma Co. Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Fuji Pharma Co. Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
10 min read
Chengdu Baiyu Pharmaceutical Co. Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
18 August 2026
A 2026 BD opportunity scan of Chengdu Baiyu Pharmaceutical Co. Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.
Latest Hotspot
12 min read
Hamman-Rich Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Hamman-Rich Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Contracture Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Contracture with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Anemia, Dyserythropoietic, Congenital Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Anemia, Dyserythropoietic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Neuroendocrine hyperplasia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Neuroendocrine hyperplasia in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.